Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoxel M vs Taxotere as Neoadjuvant Chemotherapy in Breast Cancer
NCT05207514Phase 3Terminated
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Nanoxel M in breast cancer (2 arms), sponsored by Samyang Biopharmaceuticals Corporation. Primary endpoint: Pathological Complete Response Rate. Started Mar 2022; status: terminated.
02
Drugs
Nanoxel M
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05207514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207514.